» Articles » PMID: 35359377

Anesthesia and Oncology: Friend or Foe?

Overview
Journal Front Oncol
Specialty Oncology
Date 2022 Apr 1
PMID 35359377
Authors
Affiliations
Soon will be listed here.
Abstract

Cancer is a leading cause of death, and surgery is an important treatment modality. Laboratory research and retrospective studies have raised the suspicion that the choice of anesthetics for cancer surgery might affect the course of cancerous disease. The aim of this review is to provide a critical overview of the current state of knowledge. Inhalational anesthesia with volatiles or total intravenous anesthesia (TIVA) with propofol are the two most commonly used anesthetic techniques. Most data comparing volatile anesthetics with TIVA is from either or retrospective studies. Although conflicting, data shows a trend towards favoring propofol. Opioids are commonly used in anesthesia. Data on potential effects of opioids on growth and recurrence of cancer are scarce and conflicting. Preclinical studies have shown that opioids stimulate cancer growth through the µ-opioid receptor. Opioids also act as immunosuppressants and, therefore, have the potential to facilitate metastatic spread. However, the finding of an adverse effect of opioids on tumor growth and cancer recurrence by some retrospective studies has not been confirmed by prospective studies. Regional anesthesia has not been found to have a beneficial effect on the outcome of surgically treated cancer patients, but prospective studies are scarce. Local anesthetics might have a beneficial effect, as observed in animal and studies. However, prospective clinical studies strongly question such an effect. Blood products, which may be needed during extensive cancer surgery suppress the immune system, and data strongly suggest a negative impact on cancer recurrence. The potential effects of other commonly used anesthetic agents on the outcome of cancer patients have not been sufficiently studied for drawing valid conclusions. In conclusion, laboratory data and most retrospective studies suggest a potential advantage of TIVA over inhalational anesthesia on the outcome of surgical cancer patients, but prospective, randomized studies are missing. Given the state of weak scientific evidence, TIVA may be used as the preferred type of anesthesia unless there is an individual contraindication against it. Studies on the effects of other drugs frequently used in anesthesia are limited in number and quality, and have found conflicting results.

Citing Articles

Survival benefits of propofol-based versus inhalational anesthesia in non-metastatic breast cancer patients: a comprehensive meta-analysis.

Zhang Y, Yu P, Bian L, Huang W, Li N, Ye F Sci Rep. 2024; 14(1):16354.

PMID: 39014134 PMC: 11252424. DOI: 10.1038/s41598-024-67291-4.


Uncovering essential anesthetics-induced exosomal miRNAs related to hepatocellular carcinoma progression: a bioinformatic investigation.

Huang N, Fang J, Du F, Zhou J, Li Y, Zhang X BMC Med Genomics. 2024; 17(1):154.

PMID: 38840234 PMC: 11155038. DOI: 10.1186/s12920-024-01922-7.


The Surgical Stress Response and Anesthesia: A Narrative Review.

Ivascu R, Torsin L, Hostiuc L, Nitipir C, Corneci D, Dutu M J Clin Med. 2024; 13(10).

PMID: 38792558 PMC: 11121777. DOI: 10.3390/jcm13103017.


Potential 'anti-cancer' effects of esketamine on proliferation, apoptosis, migration and invasion in esophageal squamous carcinoma cells.

Li C, Shi J, Wei S, Jia H Eur J Med Res. 2023; 28(1):517.

PMID: 37968758 PMC: 10647146. DOI: 10.1186/s40001-023-01511-x.


Propofol inhibits colon cancer cell stemness and epithelial-mesenchymal transition by regulating SIRT1, Wnt/β-catenin and PI3K/AKT/mTOR signaling pathways.

Wang R, Li S, Hou Q, Zhang B, Chu H, Hou Y Discov Oncol. 2023; 14(1):137.

PMID: 37490168 PMC: 10368601. DOI: 10.1007/s12672-023-00734-y.


References
1.
Huang X, Teng Y, Yang H, Ma J . Propofol inhibits invasion and growth of ovarian cancer cells via regulating miR-9/NF-κB signal. Braz J Med Biol Res. 2016; 49(12):e5717. PMC: 5188862. DOI: 10.1590/1414-431X20165717. View

2.
Zhang Y, Wang X, Wang Q, Ge H, Tao L . Propofol depresses cisplatin cytotoxicity via the inhibition of gap junctions. Mol Med Rep. 2016; 13(6):4715-20. DOI: 10.3892/mmr.2016.5119. View

3.
Yap A, Lopez-Olivo M, Dubowitz J, Hiller J, Riedel B . Anesthetic technique and cancer outcomes: a meta-analysis of total intravenous versus volatile anesthesia. Can J Anaesth. 2019; 66(5):546-561. DOI: 10.1007/s12630-019-01330-x. View

4.
Xu J, Xu W, Zhu J . Propofol suppresses proliferation and invasion of glioma cells by upregulating microRNA-218 expression. Mol Med Rep. 2015; 12(4):4815-20. PMC: 4581763. DOI: 10.3892/mmr.2015.4014. View

5.
Szpunar M, Burke K, Dawes R, Brown E, Madden K . The antidepressant desipramine and α2-adrenergic receptor activation promote breast tumor progression in association with altered collagen structure. Cancer Prev Res (Phila). 2013; 6(12):1262-72. PMC: 3862035. DOI: 10.1158/1940-6207.CAPR-13-0079. View